Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

ECDC: EU Off Track on 2030 Antibiotic Targets as Carbapenem-Resistant Klebsiella Infections Rise 72%

ECDC says the EU is behind on its 2030 antibiotic targets, with carbapenem-resistant Klebsiella bloodstream infections up 72% since 2019.

Published 18 Nov 2026· 5 minute read
Exterior of the European Centre for Disease Prevention and Control headquarters building in Solna, Sweden
Photo: Uvesvensson / Wikimedia Commons, CC BY-SA 4.0 (cropped). Source · Licence

The European Centre for Disease Prevention and Control (ECDC) said on 18 November 2026, European Antibiotic Awareness Day, that the EU is behind on several of its 2030 antimicrobial resistance targets, publishing new surveillance data that show bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae up 72% since 2019 against a target of a 5% reduction. The agency also released a fourth update of its rapid risk assessment on carbapenem-resistant Enterobacterales.

What happened

ECDC issued a press release headed “Urgent action needed to safeguard the effectiveness of antibiotics” and published four documents the same day: a rapid risk assessment on carbapenem-resistant Enterobacterales (fourth update), the annual epidemiological reports for 2025 on antimicrobial consumption (ESAC-Net) and antimicrobial resistance (EARS-Net), and a surveillance summary of 2025 data, according to the agency’s campaign page. ECDC Director Pamela Rendi-Wagner said: “We are still behind with several of the EU’s 2030 targets to counter antimicrobial resistance.”

CIDRAP, the University of Minnesota’s infectious disease news service, reported that the ECDC documents show a mixed picture on antibiotic consumption and resistance. It quoted the rapid risk assessment as warning that the continued increase of carbapenem-resistant Enterobacterales “will not only result in negative treatment outcomes for individuals but can also negatively impact the quality and sustainable delivery of healthcare, resulting in a very high risk to patients requiring healthcare in the EU/EEA”.

Key details: progress against the 2030 targets

Indicator (change from the 2019 baseline) 2030 target Latest ECDC finding
Total antibiotic consumption in humans 20% lower 5% lower in 2025
Share of WHO “Access” first-line antibiotics At least 65% Up from 61.1% to 62.5%
MRSA bloodstream infections 15% lower 19% lower, though increases in the past two years threaten the progress
Third-generation cephalosporin-resistant E. coli bloodstream infections 10% lower 16.4% higher
Carbapenem-resistant K. pneumoniae bloodstream infections 5% lower 72% higher

ECDC added that increased reporting of carbapenem-resistant E. coli infections, in the community as well as in healthcare settings, is an additional challenge. It noted that 90% of human antibiotic consumption takes place in the community or outpatient sector, which is why its 2026 campaign, “Care for your kids – use antibiotics wisely”, focuses on children and on the point that colds, coughs and sore throats are usually caused by viruses.

Background and context

The targets come from a Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach, adopted on 13 June 2023, which set five targets for the EU and individual member states to reach by 2030 using 2019 as the baseline year. ECDC tracks them through three networks: EARS-Net for resistance, ESAC-Net for consumption and EURGen-Net for genomic-based surveillance of multidrug-resistant bacteria. CASRAI’s guides explain EARS-Net and the role of ECDC. CIDRAP put the toll at at least 35,000 deaths a year in the EU and European Economic Area.

Reaction

Rendi-Wagner argued that faster genomic surveillance lets authorities “assess better and more rapidly how resistant bacteria spread and how they evade antibiotics”, so they can act sooner to stop transmission, guide treatment and “identify where new antibiotics are most urgently needed”. CIDRAP also reported national figures released the same week: the Australian Medical Association recorded a 4.8% rise in antibiotic prescriptions and a 25.2% rise in resistance to “critical” antibiotics in Australia in 2024; Scottish health agencies reported a 9.2% fall in human antibiotic use from 2024 to 2025; and Santé publique France reported a 9.6% fall in use over the same period, alongside a 310% increase in carbapenem-resistant Enterobacterales incidence in French hospitals since 2019. AMA President Michael Bonning said: “Antimicrobial resistance is not a future threat. It is here, it is growing, and it is already having devastating consequences.”

What it means for researchers, universities and research offices

For university hospitals, clinical microbiology laboratories and public health research groups, ECDC’s priorities are specific: infection prevention and control measures, antimicrobial stewardship, laboratory capacity and strengthened surveillance. The agency says healthcare managers must support them with adequate infection-control staffing, laboratory diagnostics, isolation capacity, training and coordination between facilities and regions. Teams that run stewardship programmes can compare their local data with the EU targets; CASRAI’s guide to the antimicrobial stewardship program and its explainer on multidrug-resistant organism prevention describe the building blocks.

For sequencing and bioinformatics groups, the stated shift towards genomic surveillance matters: ECDC says it supports faster assessment of how clones spread and where new antibiotics are most needed, which in its words helps identify where new antibiotics are most urgently needed; CASRAI’s guide to CARB-X describes one accelerator that funds such products. ECDC also published proposed guidance in 2026 on establishing and implementing infection prevention and control programmes in healthcare facilities and introduced the hyFive digital tool for hand-hygiene monitoring.

What happens next

The Council Recommendation records the Commission’s intention to report to the Council four years after adoption on the follow-up given to it, which points to 2027. Meanwhile ECDC said it conducted country visits in all member states between 2024 and 2026 and gave tailored recommendations on antimicrobial resistance and healthcare-associated infections, and it encourages every country to strengthen national coordination to prevent multidrug-resistant organisms. CASRAI’s earlier report on WHO’s AMR diagnostic tools and national plans covers the global policy track.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →